Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness
暂无分享,去创建一个
A. d’Arminio Monforte | R. Badolato | C. Tincati | G. Marchetti | M. Giacomelli | E. S. Cannizzo | A. D | Arminio Monforte
[1] Dennis Andersson,et al. Ensuring trust in COVID-19 data , 2021, Medicine.
[2] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[3] A. Sette,et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome , 2020, Science Immunology.
[4] Shakiba Darvishalipour,et al. COVID-19: combining antiviral and anti-inflammatory treatments , 2020 .
[5] M. Chiarini,et al. Immune response in children with COVID‐19 is characterized by lower levels of T‐cell activation than infected adults , 2020, European journal of immunology.
[6] F. Galluccio,et al. Treatment algorithm for COVID-19: a multidisciplinary point of view , 2020, Clinical Rheumatology.
[7] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[8] B. Lipworth,et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 , 2020, Journal of Allergy and Clinical Immunology.
[9] T. C. I. team. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States , 2020 .
[10] Catherine M. Brown,et al. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States , 2020, Nature Medicine.
[11] M. Girardis,et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia , 2020, Nature Communications.
[12] M. Netea,et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.
[13] Zhiyong Ma,et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia , 2020, The Journal of infectious diseases.
[14] Taojiao Wang,et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.
[15] Zhigang Tian,et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients , 2020, Cellular & Molecular Immunology.
[16] Xin Zhou,et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.
[17] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[18] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[19] Ivan Griffin,et al. COVID-19: combining antiviral and anti-inflammatory treatments , 2020, The Lancet Infectious Diseases.
[20] Jiyuan Zhang,et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.
[21] Chuan Qin,et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[23] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[24] J. Joh,et al. Immune Responses to Middle East Respiratory Syndrome Coronavirus During the Acute and Convalescent Phases of Human Infection , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] Hideo Baba,et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. , 2018, Cancer treatment reviews.
[26] F. Welch,et al. Causes and Consequences , 2017, Nature.
[27] P. G. Choe,et al. Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection , 2016, Journal of Korean medical science.
[28] A. Bertoletti,et al. Understanding the T cell immune response in SARS coronavirus infection , 2012, Emerging Microbes & Infections.
[29] R. Baric,et al. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon , 2012, Current Opinion in Virology.
[30] Jincun Zhao,et al. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. , 2011, The Journal of clinical investigation.
[31] Jincun Zhao,et al. T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.
[32] Christopher D. Paddock,et al. Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4+ T Cells Are Important in Control of SARS-CoV Infection , 2009, Journal of Virology.
[33] Jincun Zhao,et al. Evasion by Stealth: Inefficient Immune Activation Underlies Poor T Cell Response and Severe Disease in SARS-CoV-Infected Mice , 2009, PLoS pathogens.
[34] A. McMichael,et al. T Cell Responses to Whole SARS Coronavirus in Humans1 , 2008, The Journal of Immunology.
[35] V. Appay,et al. Immune activation and inflammation in HIV‐1 infection: causes and consequences , 2008, The Journal of pathology.
[36] R. Medzhitov,et al. Not so fast: adaptive suppression of innate immunity , 2007, Nature Medicine.
[37] Hong Tang,et al. Adaptive immune cells temper initial innate responses , 2007, Nature Medicine.
[38] Ali Danesh,et al. Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome , 2007, Journal of Virology.
[39] Mario Roederer,et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.
[40] G. Pantaleo,et al. Functional signatures of protective antiviral T‐cell immunity in human virus infections , 2006, Immunological reviews.
[41] S. Perlman,et al. Immunopathogenesis of coronavirus infections: implications for SARS , 2005, Nature Reviews Immunology.
[42] Peter Hunt,et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. , 2004, Blood.
[43] S. Rowland-Jones,et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes , 2001, Nature.
[44] F. Sallusto,et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.
[45] J V Giorgi,et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. , 1999, The Journal of infectious diseases.
[46] Mary Linnea Nelson,et al. Health Care Worker Incidents Reported in a Rural Health Care Facility , 1996, AAOHN journal : official journal of the American Association of Occupational Health Nurses.